Wesolowski R - Search Results

1

Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.

Savardekar H, Allen C, Jeon H, Li J, Quiroga D, Schwarz E, Wu RC, Zelinskas S, Lapurga G, Abreo A, Stiff A, Shaffer J, Blaser BW, Old M, Wesolowski R, Xin G, Kendra KL, Chung D, Carson WE 3rd. Savardekar H, et al. Among authors: wesolowski r. Mol Cancer Res. 2024 Mar 1;22(3):308-321. doi: 10.1158/1541-7786.MCR-22-0572. Mol Cancer Res. 2024. PMID: 38015751

2

Neoadjuvant therapy for breast cancer: assessing treatment progress and managing poor responders.

Wesolowski R, Budd GT. Wesolowski R, et al. Curr Oncol Rep. 2009 Jan;11(1):37-44. doi: 10.1007/s11912-009-0007-5. Curr Oncol Rep. 2009. PMID: 19080740 Review.

3

Use of chemotherapy for patients with bone and soft-tissue sarcomas.

Wesolowski R, Budd GT. Wesolowski R, et al. Cleve Clin J Med. 2010 Mar;77 Suppl 1:S23-6. doi: 10.3949/ccjm.77.s1.05. Cleve Clin J Med. 2010. PMID: 20179184 Free article. Review.

4

Is there a role for second-line chemotherapy in advanced gastric cancer?

Wesolowski R, Lee C, Kim R. Wesolowski R, et al. Lancet Oncol. 2009 Sep;10(9):903-12. doi: 10.1016/S1470-2045(09)70136-6. Lancet Oncol. 2009. PMID: 19717092 Review.

5

Phenoxodiol: isoflavone analog with antineoplastic activity.

Choueiri TK, Wesolowski R, Mekhail TM. Choueiri TK, et al. Among authors: wesolowski r. Curr Oncol Rep. 2006 Mar;8(2):104-7. doi: 10.1007/s11912-006-0044-2. Curr Oncol Rep. 2006. PMID: 16507219 Review.

6

Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.

Wesolowski R, Peereboom D, Weiss P, Elson P, Thomas Budd G. Wesolowski R, et al. Invest New Drugs. 2010 Aug;28(4):502-8. doi: 10.1007/s10637-009-9258-0. Epub 2009 May 12. Invest New Drugs. 2010. PMID: 19434371 Clinical Trial.

7

Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.

Burkart J, Owen D, Shah MH, Abdel-Misih SRZ, Roychowdhury S, Wesolowski R, Haraldsdottir S, Reeser JW, Samorodnitsky E, Smith A, Konda B. Burkart J, et al. Among authors: wesolowski r. J Natl Compr Canc Netw. 2018 Sep;16(9):1035-1040. doi: 10.6004/jnccn.2018.7043. J Natl Compr Canc Netw. 2018. PMID: 30181415

8

Myeloid-derived suppressor cells in breast cancer.

Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE 3rd. Markowitz J, et al. Among authors: wesolowski r. Breast Cancer Res Treat. 2013 Jul;140(1):13-21. doi: 10.1007/s10549-013-2618-7. Epub 2013 Jul 5. Breast Cancer Res Treat. 2013. PMID: 23828498 Free PMC article. Review.

9

Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.

Wesolowski R, Markowitz J, Carson WE 3rd. Wesolowski R, et al. J Immunother Cancer. 2013 Jul 15;1:10. doi: 10.1186/2051-1426-1-10. eCollection 2013. J Immunother Cancer. 2013. PMID: 24829747 Free PMC article. Review.

10

Tumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer.

Wesolowski R, Carson WE 3rd. Wesolowski R, et al. J Carcinog Mutagen. 2014 Dec;5(6):199. doi: 10.4172/2157-2518.1000199. J Carcinog Mutagen. 2014. PMID: 25750763 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

158 results

Search Page